+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Biological Drug API Manufacturing market set to grow to $7.3bn by 2022” says pharmaceutical analyst.

06 July 2018
Pharma

Visiongain’ has launched a new pharma report Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028 : Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines

The growth of the biosimilars market in the EU and the rise of generics will have a big effect on the biotech manufacturing services market. Additionally, as the patent cliff effect takes hold and many blockbuster biologics are scheduled to lose patent protection by 2019, companies will be consolidating to take advantage of this opportunity. Consolidation as a strategy gives not only manufacturing capabilities, but access to cutting-edge technology and helps foster and establish relationships that can be used to enter new markets. It is difficult for a company to determine what manufacturing capacity requirements will be in demand. The next 10 years of biotech manufacturing is estimated to have a shortfall in capacity, which is why some companies have begun plans to expand while for others, outsourcing is critical. Outsourcing as a strategy to reduce costs and increase efficiency can be a strength for biopharmaceutical companies. This trend in outsourcing will shift from the traditional model of using EU and US CMOs to outsourcing from lower emerging market CMOs, especially in Asia.

The lead analyst of the report commented “Concerns over quality and drug recalls will play a major role in biotech CMO selection in this forecast period, Visiongain believes. Selecting a CMO with significant experience in manufacturing a particular drug type will lead to more demand for the most established and largest CMOs. Although CMOs in emerging markets can offer lower cost manufacturing, a lack of experience with biopharmaceutical products will limit the level of offshoring by US and EU-based biotech’s in this forecast period unless they can increase their adherence to standard regulations.”

Leading companies featured in the report include Boehringer Ingelheim BioXcellence, Celltrion, DSM Biologics, Lonza, Samsung BioLogics, Cytovance Biologics, Fujifilm Diosynth Biotechnologies, Abbvie, GSK, Novartis

Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Antibiotics Market Report 2023-2033

The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Human Microbiome Market Report 2023-2033

The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

30 January 2023

Read